Artelo Biosciences Stock Investor Sentiment

ARTL Stock  USD 1.03  0.07  6.36%   
About 61% of Artelo Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Artelo Biosciences stock suggests that many investors are alarmed at this time. Artelo Biosciences' investing sentiment shows overall attitude of investors towards Artelo Biosciences.
  

Artelo Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Artelo Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at Macroaxis         
Does ARTELO BIOSCIENCES (NASDAQ:ARTL) have steady essential indicators based on the new hike?
Macroaxis News
over two weeks ago at benzinga.com         
Aileron Therapeutics Investigational Drug Shows Encouraging Action In Lung Fibrosis
benzinga news
a day ago at www.macroaxis.com         
Disposition of 337 shares by University Of Texastexas Am Investment Management Co of Aileron Therape...
Macroaxis News
over a month ago at news.google.com         
University of Texas Texas AM Investment Management Co. Invests 4.93 Million in Aileron Therapeutics,...
Google News at Macroaxis
over a year ago at news.google.com         
Is Histogen Inc a Smart Choice in Biotechnology Tuesday - InvestorsObserver
Google News at Macroaxis
over a year ago at investorplace.com         
Why Is Histogen Stock Up 37 percent Today?
sbwire news
over two weeks ago at finance.yahoo.com         
Mirum Pharmaceuticals, Inc. Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over three weeks ago at gurufocus.com         
Curis Stock Plummets Over 5 percent Amid Lack of Institutional Ratings
Gurufocus Stories at Macroaxis
over a year ago at globenewswire.com         
Timber Pharmaceuticals Discloses Communication From NYSE American
Macroaxis News: globenewswire.com
over two months ago at news.google.com         
Salarius Pharmaceuticals Stock Quotes, Forecast and News Summary - Benzinga
Google News at Macroaxis
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Increases Stake in Salarius Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Maurice Zauderer of 46153 shares of Vaccinex at 3.25 subject to Rule 16b-3
Macroaxis News
over three weeks ago at globenewswire.com         
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b2 Trial of Pepinemab at Clinical Trials on Alzhe...
Macroaxis News: globenewswire.com
over two months ago at news.google.com         
Vaccinex stock hits 52-week low at 4.17 amid sharp annual decline - Investing.com
Google News at Macroaxis
over a week ago at seekingalpha.com         
Vaccinex reports Q3 figures
seekingalpha News
over a week ago at news.google.com         
NumberGoUpTech Price TECH Live Price Chart, Market Cap News Today - CoinGecko Buzz
Google News at Macroaxis
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeutics Corp
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Novak Alfred J of 5000 shares of Pasithea Therapeutics at 8.13 subject to Rule 16b-3
Macroaxis News
over two months ago at seekingalpha.com         
Pasithea Therapeutics drops 19 percent on 5M private placement
seekingalpha News
3 days ago at thelincolnianonline.com         
Pasithea Therapeutics Corporation Enters into At The Market Offering Agreement with H.C. Wainwright ...
news
3 days ago at finance.yahoo.com         
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa Abuse Deterrent Transdermal...
Yahoo News
over a year ago at marketwatch.com         
Zivo Bioscience Shares Jump Premarket After Dropping Plans for Securities Offering
marketwatch News
over a year ago at news.google.com         
Flora Growth to effect 1-for-20 reverse stock split - Seeking Alpha
Google News at Macroaxis
over a year ago at marketbeat.com         
ZIVO Bioscience Price Target and Analyst Ratings 2023
Marketbeat News
over a year ago at businesswire.com         
ZIVO Bioscience Announces Pricing of 4.0 Million Registered Direct Offering Priced At-The-Market
businesswire News
over a week ago at www.macroaxis.com         
Acquisition by Beaver Carolyn of 15000 shares of MediciNova at 5.4 subject to Rule 16b-3
Macroaxis News
over two weeks ago at globenewswire.com         
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office forNew Patent...
Macroaxis News: globenewswire.com
over two months ago at finance.yahoo.com         
MNOV MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS
Yahoo News
over two months ago at news.google.com         
StockNews.com Initiates Coverage on MediciNova - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Yahoo News
over a month ago at www.macroaxis.com         
Disposition of 1300000 shares by Grissinger Michael of Akari Therapeutics at 0.0218 subject to Rule ...
Macroaxis News
over two months ago at finance.yahoo.com         
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Yahoo News
over two weeks ago at globenewswire.com         
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
Macroaxis News: globenewswire.com
over a year ago at thelincolnianonline.com         
Axcella Health Stock Price Down 3
news
over a year ago at finance.yahoo.com         
Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death
Yahoo News
over a year ago at hawaiinewsnow.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates MGTA, CHRA, STSA
news
Far too much social signal, news, headlines, and media speculation about Artelo Biosciences that are available to investors today. That information is available publicly through Artelo media outlets and privately through word of mouth or via Artelo internal channels. However, regardless of the origin, that massive amount of Artelo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Artelo Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Artelo Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Artelo Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Artelo Biosciences alpha.

Artelo Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 667 shares by Blayney Douglas of Artelo Biosciences at 15.0 subject to Rule 16b-3
09/05/2024
2
ARTL stock touches 52-week low at 1.12 amid market challenges - Investing.com Canada
09/10/2024
3
Artelo Biosciences, Inc. Short Interest Down 18.3 percent in October
10/29/2024
4
Artelo Biosciences Reports Third Quarter 2024 Financial Results andProvides Business Update
11/12/2024
5
Artelo Biosciences Shares Drop Amidst Biotech Sector Movements
11/27/2024
When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:
Check out Artelo Biosciences Hype Analysis, Artelo Biosciences Correlation and Artelo Biosciences Performance.
For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Return On Assets
(0.54)
Return On Equity
(0.89)
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.